These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1231 related articles for article (PubMed ID: 25471252)

  • 41. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
    Cornely OA; Leguay T; Maertens J; Vehreschild MJGT; Anagnostopoulos A; Castagnola C; Verga L; Rieger C; Kondakci M; Härter G; Duarte RF; Allione B; Cordonnier C; Heussel CP; Morrissey CO; Agrawal SG; Donnelly JP; Bresnik M; Hawkins MJ; Garner W; Gökbuget N;
    J Antimicrob Chemother; 2017 Aug; 72(8):2359-2367. PubMed ID: 28575414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.
    Peghin M; Monforte V; Martin-Gomez MT; Ruiz-Camps I; Berastegui C; Saez B; Riera J; Ussetti P; Solé J; Gavaldá J; Roman A
    Transpl Int; 2016 Jan; 29(1):51-62. PubMed ID: 26339864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
    Gahn B; Schub N; Repp R; Gramatzki M
    Eur J Med Res; 2007 Aug; 12(8):337-40. PubMed ID: 17933709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis.
    Nihtinen A; Anttila VJ; Ruutu T; Juvonen E; Volin L
    Transpl Infect Dis; 2012 Feb; 14(1):24-32. PubMed ID: 21749589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
    Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution.
    Tzadok R; Shapira MY; Moses AE; Or R; Block C; Strahilevitz J
    Mycoses; 2015 Dec; 58(12):694-8. PubMed ID: 26429354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus.
    Canada TW; Weavind LM; Augustin KM
    Ann Pharmacother; 2003 Jan; 37(1):70-3. PubMed ID: 12503936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease.
    Zhang S; He Y; Jiang E; Wei J; Yang D; Zhang R; Zhai W; Zhang G; Wang Z; Zhang L; Liu L; Han M; Feng S
    Future Microbiol; 2017 Nov; 12():1371-1379. PubMed ID: 28880124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.
    Tollemar J; Klingspor L; Ringdén O
    Clin Microbiol Infect; 2001; 7 Suppl 2():68-79. PubMed ID: 11525221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001).
    Safdar A; Singhal S; Mehta J
    Cancer; 2004 Jun; 100(11):2456-61. PubMed ID: 15160352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.
    O'Donnell MR; Schmidt GM; Tegtmeier BR; Faucett C; Fahey JL; Ito J; Nademanee A; Niland J; Parker P; Smith EP
    J Clin Oncol; 1994 Apr; 12(4):827-34. PubMed ID: 8151325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
    Marks DI; Liu Q; Slavin M
    Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
    Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
    Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.